GWPH - GW Pharmaceuticals: Price Decline And Mixed Prospects
GW Pharmaceuticals Plc (NASDAQ: GWPH) is a well-rated stock according to Yahoo Finance and Bloomberg analyst consensus, however, I see 2 major risks associated with the firm's competitive position and investment prospects long term. I would caution investors to consider these risks before initiating a long position.
Background
GW Pharmaceuticals Plc is an established UK company with a 20-year-old-long history, researching and developing cannabinoid prescription medicines for the treatment of cancer pain, multiple sclerosis, neuropathic pain, and epilepsy. The two main products are Sativex, approved in the UK, Canada, New Zealand and several other